Havrix

Havrix is a hepatitis A vaccine (inactivated) that contains inactivated hepatitis A virus and the adjuvant algeldrate. It is supplied as an injectable solution for intramuscular administration and is marketed in the European Union. The vaccine is prescribed to stimulate active immunity against hepatitis A infection and is available only by prescription.

Havrix is indicated for the prevention of hepatitis A infection in individuals at risk. It is used in a variety of clinical situations to provide protective immunity.

- Routine immunization of adults and children aged 1 year and older. - Pre‑travel protection for persons traveling to regions with high hepatitis A prevalence. - Outbreak control in communities or institutions where hepatitis A cases have occurred. - Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A virus. - Protection of people with chronic liver disease or clotting factor disorders.

Side effects of Havrix are generally mild and transient, but serious reactions can occur in rare cases.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or malaise. - Muscle aches. - Nausea.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat. - Guillain‑Barré syndrome (rare neurological disorder). - High fever persisting more than 48 hours. - Seizures (rare).

Before administering Havrix, certain precautions should be considered to ensure safety.

- Do not vaccinate individuals with a known severe allergy to any vaccine component, including algeldrate. - Use caution in pregnant or breastfeeding women; discuss potential benefits and risks with a healthcare professional. - Immunocompromised patients may have a reduced immune response; vaccination should be evaluated on a case‑by‑case basis. - Defer vaccination in persons with an acute moderate or severe febrile illness until recovery. - Children under 1 year of age are not approved for this vaccine. - Ensure the recommended dosing interval is maintained for optimal protection.

Havrix has limited known drug interactions, but certain situations require attention.

Avoid: - Simultaneous administration of other injectable vaccines unless specifically recommended by guidelines. - Use in individuals who have received a recent blood product that may contain hepatitis A antibodies.

Use with caution: - Patients receiving immunosuppressive therapy, as vaccine efficacy may be reduced. - Concurrent use of antipyretics or analgesics that could mask fever after vaccination. - Individuals on long‑term corticosteroid therapy. - Co‑administration with live vaccines; maintain appropriate interval as advised.